Vaccine and anti-viral drug development for SARS-CoV2
Submission Deadline: 31 May 2022
Guest Editor
Laboratory of Influenza Research, College of Veterinary Medicine, Chungnam National University, Yuseong Gu, Daejeon, Republic of Korea
Interests: vaccine; epidemiology; pathogenicity on influenza virus and SARS-CoV-2
Special Issue in IMR Press journals
Special Issue in Research on Influenza Viruses
Special Issue Information
Dear Colleagues，
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) known as covid-19 still causes tremendous burden on humans. This virus has many variants such as Alpha, Beta, Gamma and Delta. Some variants have the potential for the increased trasnsmissibility, increased virulence, or reduced effectiveness of vaccines against current vaccines.
We need to develop better vaccine for protecting people from being infected from emerging variants SARS-CoV2 and anti-viral drugs to treat humans infected with SARS-CoV2. The goal of this special issue is to publish new approach to vaccines and anti-viral drugs for SARS-CoV2. Interesting researchers are encouraged to submit short reports, and full papers based on animal studies and human clinical trials.
Prof. Sang Heui Seo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted manuscripts should be well formatted in good English.
Published Papers (10)
Front. Biosci. (Landmark Ed) 2022, 27(11), 316; https://doi.org/10.31083/j.fbl2711316
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
Front. Biosci. (Landmark Ed) 2022, 27(11), 306; https://doi.org/10.31083/j.fbl2711306
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
Front. Biosci. (Landmark Ed) 2022, 27(9), 257; https://doi.org/10.31083/j.fbl2709257
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
Front. Biosci. (Landmark Ed) 2022, 27(6), 180; https://doi.org/10.31083/j.fbl2706180
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
Front. Biosci. (Landmark Ed) 2022, 27(5), 157; https://doi.org/10.31083/j.fbl2705157
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
Front. Biosci. (Landmark Ed) 2022, 27(4), 113; https://doi.org/10.31083/j.fbl2704113
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
Front. Biosci. (Landmark Ed) 2022, 27(2), 65; https://doi.org/10.31083/j.fbl2702065
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
Front. Biosci. (Landmark Ed) 2022, 27(2), 48; https://doi.org/10.31083/j.fbl2702048
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
Front. Biosci. (Landmark Ed) 2022, 27(1), 3; https://doi.org/10.31083/j.fbl2701003
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
Front. Biosci. (Landmark Ed) 2021, 26(12), 1493-1502; https://doi.org/10.52586/5043
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)